I6Q-MC-BIFC Subcutaneous Buffer Injections in Healthy Subjects

  • Research type

    Research Study

  • Full title

    Protocol I6Q-MC-BIFC- A Randomized Study of Subcutaneous Injections of Buffer Matrices in Healthy Subjects

  • IRAS ID

    236695

  • Contact name

    Firas Almazedi

  • Contact email

    firas.almazedi@covance.com

  • Sponsor organisation

    Eli Lilly and Company

  • Duration of Study in the UK

    0 years, 3 months, 2 days

  • Research summary

    Pain from subcutaneous (SC) injections (an injection under the skin) of medications is common and can discourage people from taking their medication. What may contribute to the pain experienced with injected medications is the buffer (a substance that is used to help the drug be absorbed into the body) that is given with the medication, as different buffers with varying strengths can be used.
    This study is being carried out to compare the amount of pain at the injection-site between 3 different types of buffer at different strengths. This could help to improve future medications by reducing the amount of pain people experience with injectable medications.
    The buffers injected in this study will contain inactive ingredients only. Participants will not receive any drug in this Study.
    Up to 55 participants will be participating in this study. The total study duration will be up to 7 weeks from the time of screening to the last follow-up.

  • REC name

    North West - Greater Manchester West Research Ethics Committee

  • REC reference

    17/NW/0696

  • Date of REC Opinion

    8 Dec 2017

  • REC opinion

    Favourable Opinion